Our Company Our Products Our Research For Investors Newsroom
Our Company

Sucampo Supported Publications


2008

  1. Chey WD, Saad RJ, Panas RM, Wahle A, Ueno R. 2008. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: results from a randomized withdrawal study. Gastroenterology 134(4 Suppl 1):A-401 [abstract M1706].
  2. Chey WD, Drossman DA, Scott C, Panas RM, Ueno R. 2008. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology 134(4 Suppl 1):A-215 [abstract S1272].
  3. Chey WD, Drossman DA, Scott C, Panas RM, Ueno R. 2008. What symptoms drive global symptom improvement with lubiprostone in patients with irritable bowel syndrome and constipation: data from two multicenter, randomized, placebo-controlled trials. Gastroenterology 134(4 Suppl 1):A-28 [abstract 157].
  4. Cuppoletti J, Malinowska DH, Tewari K, Chakrabarti J, Ueno R. 2008. ClC-2-targeted siRNA eliminates lubiprostone activation of Cl-currents in T84 cells. Gastroenterology 134(4 Suppl 1):A-582 [abstract T1877].
  5. Cuppoletti J, Malinowska DH, Chakrabarti J, Ueno R. 2008. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat 86(1-4):56-60.
  6. Cuppoletti J, Malinowska DH, Tewari K, Chakrabarti J, Mende K, Ueno R. 2008. Lubiprostone activation of Cl-currents does not invivle Ca2+,cAMP, or PKA. Gastroenterology 134(4 Suppl 1):A-581-A582 [abstract T1876].
  7. Dong H, Contreras C, Dong X, Barrett KE. 2008. Effect of lubiprostone on duodenal mucosal bicarbonate secretion. Gastroenterology 134(4 Suppl 1):A-479 [abstract T1081].
  8. Drossman DA, Chey WD, Scott C, Panas RM, Ueno R. 2008. Health-related quality of life in adults with irritable bowel syndrome with constipation: results of a combined analysis of two phase 3 studies with lubiprostone. Gastroenterology 134(4 Suppl 1):A-469 [abstract T1036].
  9. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. 2008. Clinical trial: phase 2 trial of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 27(8):685-96.
  10. Johanson JF, Morton D, Geenen J, Ueno R. 2008. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 103(1):170-7.
  11. Nighot MP, Ueno R, Roerig B, Ryan KA, Blikslager AT, Moeser AJ. 2008. Gastroprotective properties of cobiprostone against acid and NSAID-induced mucosal injury in porcine gastric mucosa. Gastroenterology 134(4 Suppl 1):A-705 [abstract W1738].
  12. Osama H, Kuno S, Roerig B, Ueno R. 2008. Effect of cobiprostone on naproxen-induced gastric ulcers in rats. Gastroenterology 134(4 Suppl 1):A-738 [abstract W1939].
  13. Sun X, Xia Y, Liu S, Wang Y, Qu M, Wang X, Wang G, Needleman B, Mikami DJ, Melvin WS, Bohn LM, Ueno R, Wood JD. 2008. Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in the human jejunum. Gastroenterology 134(4 Suppl 1):A-122 [abstract 844].
  14. Wang Y, Cooke HJ, Bohn LM, Ueno R, Wood JD. 2008. Lubiprostone enhances histamine H2 receptor-mediated cyclical chloride secretion in the guinea pig colon. Gastroenterology 134(4 Suppl 1):A-543 [abstract T1380].
Back to Top

2007

  1. Cuppoletti J, Malinowska DH, Tewari KP, Chakrabarti J, Ueno R. 2007. Cellular and molecular effects of unoprostone as a BK channel activator. Biochim Biophys Acta 1768(5):1083-92.
  2. Cuppoletti J, Mende K, Malinowska DH, Ueno R. 2007. Cobiprostone is a type-2 chloride channel activator that protects against NSAID-induced cellular damage. Am J Gastroenterol 102(2 Suppl): S163-S164 [abstract 126].
  3. Cuppoletti J, Malinowska DH, Ramisetti S, Ueno R. 2007. Lubiprostone activates Cl- currents in Caco-2 cells from the apical side. Gastroenterology 132(4 Suppl 2):A-576 [abstract T1887].
  4. Drossman DA, Chey W, Panas R, Wahle A, Scott C, Ueno R. 2007. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve-week, randomized, placebo-controlled, double-blind trials. Gastroenterology 132(7):2586-7.
  5. Eaton DC, Bao H, Liu L, Ueno R. 2007. Lubiprostone activates single chloride channels in the apical membrane of A6 epithelial cells. Gastroenterology 132(4 Suppl 2):A-574 [abstract T1875].
  6. Engelke K, Harris S, Roerig B, Ueno R. 2007. Developmental toxicity studies of lubiprostone, a novel type-2 chloride channel activator, in pregnant rats and rabbits. Int J Toxicol 26(6):600-1 [abstract P5].
  7. Engelke K, Harris S, Roerig B, Ueno R. 2007. Effect of lubiprostone, a novel type-2 chloride channel (ClC-2) activator, in pregnant rhesus monkeys. Gastroenterology 132(4 Suppl 2):A-534 [abstract T1683].
  8. Fei G, Liu S, Qu M, Wang G, Wang X, Zou F, Xia Y, Bohn L, Wood J. 2007. Lubiprostone bypasses morphine-induced inhibition of secretion in guinea-pig intestine. Neurogastroenterol Motil 19(3):60-1 [abstract PS067].
  9. Fei G, Liu S, Wang G, Qu M, Wang X, Zou F, Du Y, Xia Y, Bohn LM, Wood JD. 2007. Stimulation of mucosal secretion by lubiprostone in guinea-pig small intestine and colon. Gastroenterology 132(4 Suppl 2):A-683 [abstract W1206].
  10. Johanson JF, Ueno R. 2007. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 25(11):1351-61.
  11. MacDonald KD, McKenzie KR, Vij N, Henderson MJ, Zeitlin PL. 2007. Activation of nasal epithelial ClC-2 channels rescues chloride transport in cystic fibrosis mice. Pediatr Pulmonol 42(Suppl 30):231 [abstract 87].
  12. Moeser AJ, Nighot PK, Roerig B, Ueno R, Blikslager AT. 2007. Comparison of mucosal reparative responses of lubiprostone and polyethylene glycol (PEG) laxative in ischemia-injured porcine ileum. Gastroenterology 132(4 Suppl 2):A-191 [abstract S1186].
  13. Moeser AJ, Nighot PK, Engelke KJ, Ueno R, Blikslager AT. 2007. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 292(2):G647-G656.
  14. Osama H, Kuno S, Roerig B, Ueno R. 2007. Effects of cobiprostone on indomethacin- and stress-induced gastric ulcers in rats. Am J Gastroenterol 102(2 Suppl):S159 [abstract 115].
  15. Rivera E, Wahle A, Joswick TR, Ueno R. 2007. Lubiprostone, a novel type-2 chloride channel (ClC-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation. Gastroenterology 132(4 Suppl 2):A-191-A-192 [abstract S1188].
  16. Sprenger C, Copa A, Morganroth J, Panas R, Ueno R. 2007. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiographic results. Gastroenterology 132(4 Suppl 2):A-325 [abstract S2136].
  17. Ueno R, Roerig B, Osama H. 2007. Lubiprostone induces intestinal fluid secretion in rats at clinically relevant doses. Neurogastroenterol Motil 19(5):433-4 [abstract 43].
Back to Top

2006

  1. Camilleri M, Bharucha AE, Ueno R, Burton D, Thomforde GM, Baxter K, McKinzie S, Zinsmeister AR. 2006. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 290(5):G942-G947.
  2. Johanson J, Wahle A, Ueno R. 2006. Efficacy and safety of lubiprostone in a subgroup of constipation patients diagnosed with irritable bowel syndrome with constipation (IBS-C). Am J Gastroenterol 101(2 Suppl):S491 [abstract 1270].
  3. Johanson JF, Panas R, Holland PC, Ueno R. 2006. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterology 130(4 Suppl 2):A-317 [abstract M1171].
  4. Johanson JF, Panas R, Holland PC, Ueno R. 2006. Long-term safety and efficacy of lubiprostone for the treatment of chronic idiopathic constipation. Neurogastroenterol Motil 18(8):675 [abstract 30].
  5. Ueno R, Osama H, Engelke KJ. 2006. Effects of lubiprostone on morphine-induced constipation and analgesia. Gastroenterology 130(4 Suppl 2):A-373-A-374 [abstract M1810].
  6. Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. 2006. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs non-elderly subjects. Gastroenterology 130(4 Suppl 2):A-189 [abstract S1262].
  7. Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. 2006. Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation in male vs female subjects. Gastroenterology 130(4 Suppl 2):A-322 [abstract M1195].
  8. Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. 2006. Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation in male patients. Neurogastroenterol Motil 18(8):735 [abstract 224].
  9. Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. 2006. Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation in elderly patients. Neurogastroenterol Motil 18(8):734-5 [abstract 222].
  10. Ueno R, Wahle A, Panas R, Joswick TR, Rivera E. 2006. Evaluation of safety and efficacy in twelve-month study of lubiprostone for the treatment of chronic idiopathic constipation. Am J Gastroenterol 101(2 Suppl):S491 [abstract 1269].
  11. Ueno R, Wahle A. 2006. Increased bowel movements are highly correlated with improvements in secondary efficacy assessments in constipated subjects treated with lubiprostone. Am J Gastroenterol 101(2 Suppl):S488-S489 [abstract 1263].
  12. Ueno R, Panas R, Wahle A, Zhu Y, Holland PC. 2006. Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterology 130(4 Suppl 2):A-188 [abstract S1260].
  13. Ueno R, Panas R, Wahle A, Zhu Y, Holland PC. 2006. Long-term safety and efficacy of lubiprostone for the treatment of chronic idiopathic constipation in elderly and non-elderly patients. Neurogastroenterol Motil 18(8):735 [abstract 223].
  14. Ueno R, Wahle A, Joswick TR. 2006. Lubiprostone for the treatment of chronic constipation: patient symptom ratings. Am J Gastroenterol 101(2 Suppl):S492 [abstract 1273].
  15. Ueno R, Wahle A. 2006. Lubiprostone produces spontaneous bowel movements within 24 and 48 hours in patients with chronic constipation. Am J Gastroenterol 101(2 Suppl):S490-S491 [abstract 1268].
  16. Ueno R, Wahle A, Rivera E. 2006. Pooled analysis of the most frequent adverse events associated with the use of lubiprostone. Am J Gastroenterol 101(2 Suppl):S489 [abstract 1264].
Back to Top

2005

  1. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. 2005. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week phase III study. Am J Gastroenterol 100(9 Suppl):S324-S325 [abstract 884].
  2. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. 2005. Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation. Am J Gastroenterol 100(9 Suppl):S331 [abstract 903].
  3. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. 2005. Phase III patient assessments of the effects of lubiprostone, a chloride channel-2 (ClC-2) activator, for the treatment of constipation. Am J Gastroenterol 100(9 Suppl):S329-S330 [abstract 899].
  4. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. 2005. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primary efficacy. Am J Gastroenterol 100(9 Suppl):S328-S329 [abstract 896].
  5. Ueno R, Engelke KJ, Osama H. 2005. Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle. Neurogastroenterol Motil 17(4):625-6 [abstract 77].
  6. Ueno R. 2005. Multiple, escalating, oral-dose study to assess the safety, tolerance and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol Motil 17(4):626 [abstract 78].
  7. Ueno R, Perentesis GP, Engelke KJ, Kawai Y. 2005. Pharmacokinetic profile of lubiprostone, a selective GI chloride channel activator, after a single oral dose in multiple animal species. Neurogastroenterol Motil 17(4):625 [abstract 76].
Back to Top

2004

  1. Cuppoletti J, Malinowska DH, Tewari KP, Li QJ, Sherry AM, Patchen ML, Ueno R. 2004. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 287(5):C1173-C1183.
  2. Cuppoletti J, Malinowska DH, Tewari KP, Sherry AM, Patchen ML, Ueno R. 2004. SPI-8811 activates human bronchial epithelial cell chloride transport and recombinant human ClC-2 chloride currents. Pediatr Pulmonol 38(Suppl 27):245-6 [abstract 167].
  3. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. 2004. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology 126(4 Suppl 2):A-100 [abstract 749].
  4. Ueno R, Osama H, Habe T, Engelke K, Patchen M. 2004. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterology 126(4 Suppl 2):A-298 [abstract M1109].levels. Gastroenterology 126(4 Suppl 2):A-298 [abstract M1109].

Last Updated 07/08/2008